Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration

Article Cardiac & Cardiovascular Systems

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

Gerasimos Filippatos et al.

Summary: Finerenone reduces the incidence of new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of a history of HF.

CIRCULATION (2022)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

Peter Rossing et al.

Summary: The study showed that finerenone significantly reduced the risk of kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. There was no clear interaction between GLP-1RA use and the treatment effect of finerenone, indicating consistent effects on kidney and cardiovascular outcomes regardless of GLP-1RA use.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Rajiv Agarwal et al.

Summary: The study found that finerenone can reduce the risk of kidney disease and cardiovascular events in patients with type 2 diabetes. Screening patients for albuminuria can help reduce the burden of cardiovascular and kidney disease.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Urology & Nephrology

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

Rajiv Agarwal et al.

Summary: The study reveals that treatment with finerenone is associated with an increased risk of hyperkalemia, but routine monitoring and management strategies can mitigate its impact.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Transplantation

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

Rajiv Agarwal et al.

Summary: This study compares the effects of two clinical trials and highlights the similar cardiorenal benefits of finerenone and canagliflozin.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Add to Collection

Article Urology & Nephrology

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing et al.

Summary: The FIDELIO-DKD study investigated the treatment effect of finerenone in patients with CKD and T2D, showing that finerenone can improve UACR and have beneficial effects on kidney and cardiovascular outcomes, regardless of whether patients were also using SGLT-2i.

KIDNEY INTERNATIONAL REPORTS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism

Luis M. Ruilope et al.

TRENDS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Article Peripheral Vascular Disease

Blood pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes

Luis M. Ruilope et al.

Summary: This analysis explored the relationship between office systolic blood pressure (SBP) and cardiorenal outcomes with finerenone in FIDELIO-DKD trial. Finerenone significantly reduced office SBP across all baseline SBP quartiles and improved cardiorenal outcomes. Reductions in office SBP accounted for a small proportion of the treatment effect on cardiorenal outcomes.

HYPERTENSION (2022)

Add to Collection

Review Urology & Nephrology

KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

Ian H. de Boer et al.

Summary: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) is a focused update of the 2020 guideline, providing treatment recommendations for clinicians treating diabetes and CKD based on systematic reviews of relevant studies.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Gerasimos Filippatos et al.

Summary: In the FIDELIO-DKD study, finerenone was found to reduce the risk of new-onset atrial fibrillation/flutter in patients with CKD and T2D. The effect on kidney or cardiovascular events was not significantly impacted by baseline history of atrial fibrillation/flutter.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal